Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Am J Obstet Gynecol. 2002;187(1):116–126. doi:10.1067/mob.2002.12570412114899
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. doi:10.1016/j.eururo.2006.09.01917049716
   PubMed Web of Science ®Google Scholar
• Puckrein G, Walker D, Xu L, et al. The prevalence and forecast prevalence of overactive bladder in the medicare population. Clin Med Insights Urol. 2019;12:1–8. doi:10.1177/1179561119847464
   Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336. doi:10.1007/s00345-002-0301-412811491
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766. doi:10.1046/j.1464-410x.2001.02228.x11412210
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352–360. doi:10.1111/j.1464-410X.2009.08427.x19281467
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087. doi:10.1016/j.urology.2010.08.03921256571
   PubMed Web of Science ®Google Scholar
• Reynolds WS, Fowke J, Dmochowski R. The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep. 2016;11(1):8–13. doi:10.1007/s11884-016-0344-927057265
   PubMedGoogle Scholar
• Wada Y, Yoshida M, Kitani K, et al. Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther. 1995;330(1):76–89.8849312
   PubMedGoogle Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282. doi:10.1111/j.1464-410X.2009.09036.x19912188
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013;35(11):1744–1751. doi:10.1016/j.clinthera.2013.08.01724091072
   PubMed Web of Science ®Google Scholar
• Davila GW. Transdermal oxybutynin in the treatment of overactive bladder. Clin Interv Aging. 2006;1(2):99–105. doi:10.2147/ciia.2006.1.2.9918044106
   PubMed Web of Science ®Google Scholar
• American Urological Association. Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults: an AUA/SUFU guideline (2019) AUA/SUFU guideline: published 2012; amended 2014. Endorsed by the American Urogynecologic Society (AUGS); 2019 Available from: https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline. Accessed 225, 2020.
   Google Scholar
• Buckhard FC, Bosch JLHR, Cruz F, et al. EAU guidelines on urinary incontinence in adults. European Association of Urology; 2018 Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urinary-Incontinence-2018-large-text.pdf. Accessed 225, 2020.
   Google Scholar
• Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991;252(2):562–567.
   Google Scholar
• Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999;21(4):634–642. doi:10.1016/S0149-2918(00)88316-210363730
   PubMed Web of Science ®Google Scholar
• Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60(5 Suppl 1):82–88. doi:10.1016/S0090-4295(02)01803-412493364
   PubMed Web of Science ®Google Scholar
• Thüroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991;145(4):813–816. doi:10.1016/S0022-5347(17)38459-82005707
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–763. doi:10.1016/j.eururo.2008.06.08018632201
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Starkman JS, Davila GW. Transdermal drug delivery treatment for overactive bladder. Int Braz J Urol. 2006;32(5):513–520. doi:10.1590/S1677-5538200600050000317081319
   PubMedGoogle Scholar
• Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 1997;157(3):1093–1097. doi:10.1016/S0022-5347(01)65148-69072550
   PubMed Web of Science ®Google Scholar
• Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78(6):696–702. doi:10.4065/78.6.69612934778
   PubMed Web of Science ®Google Scholar
• Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol. 2001;52(4):409–417. doi:10.1046/j.0306-5251.2001.01463.x11678784
   PubMed Web of Science ®Google Scholar
• Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001;18(7):1029–1034. doi:10.1023/A:101095683211311496941
   PubMed Web of Science ®Google Scholar
• Zobrist RH, Quan D, Thomas HM, Stanworth S, Sanders SW. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res. 2003;20(1):103–109. doi:10.1023/A:102225901105212608543
   PubMed Web of Science ®Google Scholar
• Baldwin CM, Keating GM. Transdermal oxybutynin. Drugs. 2009;69(3):327–337. doi:10.2165/00003495-200969030-0000819275276
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW. Transdermal oxybutynin study group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166(1):140–145.11435842
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168(2):580–586. doi:10.1016/S0022-5347(05)64684-812131314
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237–242. doi:10.1016/S0090-4295(03)00356-X12893326
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23(4):263–270. doi:10.1007/s00345-005-0012-816151816
   PubMed Web of Science ®Google Scholar
• Cartwright R, Srikrishna S, Cardozo L, Robinson D. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011;107(1):70–76. doi:10.1111/j.1464-410X.2010.09508.x20626389
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Uchida E, Higo N, et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. Int J Urol. 2014;21(6):586–593. doi:10.1111/iju.1237224350662
   PubMed Web of Science ®Google Scholar
• Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract. 2008;62(1):27–38. doi:10.1111/j.1742-1241.2007.01625.x17983434
   PubMed Web of Science ®Google Scholar
• Vozmediano-Chicharro R, Madurga B, Blasco P. Efficacy of transdermal oxybutynin in the treatment of overactive bladder syndrome: does it make sense using it in 2017? Adv Urol. 2018;2018:6782736. doi:10.1155/2018/678273630151004
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007;99(4):836–844. doi:10.1111/j.1464-410X.2006.06658.x17187655
   PubMed Web of Science ®Google Scholar
• Newman DK. The MATRIX study: evaluating the data in older adults. Director. 2008;16(2):21–24.19343880
   PubMedGoogle Scholar
• Pizzi LT, Talati A, Gemmen E, Dahl NV, Bunz TJ, Sand PK. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009;27(4):329–339. doi:10.2165/00019053-200927040-0000519485428
   PubMed Web of Science ®Google Scholar
• Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol. 2006;195(6):1730–1735. doi:10.1016/j.ajog.2006.08.01317132474
   PubMed Web of Science ®Google Scholar
• Vozmediano-Chicharro R, Blasco Hernández P, Madurga-Patuel B. Tolerabilidad, persistencia y satisfacción. Estudio de cohortes retrospectivas realizado en condiciones de práctica clínica en pacientes con síndrome de vejiga hiperactiva tratados con oxibutinina transdérmica. Estudio OSCAR. Arch Esp Urol. 2017;70(6):561–569.28678009
   PubMed Web of Science ®Google Scholar
• Herbison P, McKenzie JE. Which anticholinergic is best for people with overactive bladders? A network meta-analysis. Neurourol Urodyn. 2019;38(2):525‐534. doi:10.1002/nau.23893
   Web of Science ®Google Scholar
• Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084. doi:10.1001/jamainternmed.2019.0677
   PubMed Web of Science ®Google Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315. doi:10.1136/bmj.k131529695481
   PubMed Web of Science ®Google Scholar
• Müller-Arteaga C, Batista-Miranda JE, Zubiaur Libano C, et al. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin. Actas Urol Esp. 2019;43(3):143–150. doi:10.1016/j.acuro.2018.07.00530470585
   PubMed Web of Science ®Google Scholar
• Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009;74(4):741–745. doi:10.1016/j.urology.2009.05.00819628264
   PubMed Web of Science ®Google Scholar
• Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol. 2009;182(4):1548–1554. doi:10.1016/j.juro.2009.06.05819683731
   PubMed Web of Science ®Google Scholar
• Crespo C, Blasco P, Guigini M, Galván J. Clinical and economic evaluation of transdermal oxybutynin in the treatment of overactive bladder in Spain. JHEOR. 2018;5(2):194–205. doi:10.36469/9811
   Google Scholar